In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Endosense brings in €25mm through its Series B venture round

Executive Summary

Endosense (catheter ablation for cardiac arrhythmias) has raised €25mm ($36mm) through the closing of its Series B venture round. Edmond de Rothschild Investment Partners (EdRIP) led the financing and was joined by NeoMed, GIMV, VI Partners, Sectoral Asset Management, Ysios Capital Partners, and Initiative Capital Romandie. Endosense will use the money for European commercialization (it gained the CE Mark four months ago) and a US PMA study of its TactiCath ablation catheter. Representatives from EdRIP, GIMV, and VI will take seats on the company's board.
Deal Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register